Impact of Exercise and Weight Loss on Breast Cancer Lymphedema Outcomes

Lymphedema is a common complication of curative breast cancer treatment, occurring in as many as 50% of patients undergoing axillary lymph node dissection. Because lymphedema occurs more commonly in patients with excess body weight, current guidelines recommend weight loss and home-based exercise as a strategy to manage breast cancer-related lymphedema. However, this recommendation has not […]

Read More

New Guidelines on Management of Venous Thromboembolism

Cancer patients are significantly more likely to develop venous thromboembolism (VTE) than people without cancer. Appropriate risk assessment, prophylaxis, and management of VTEs is essential to prevent the long-term complications and risk of death from deep vein thrombosis and pulmonary embolism. In a new Clinical Practice Guideline released by the American Society for Clinical Oncology […]

Read More

Antidepressants Linked to Reduced Cancer Mortality

Patients with cancer often experience depression and anxiety, and these comorbid conditions are independent risk factors for premature mortality. Many patients with cancer take antidepressants to manage these conditions, but little is known about the link between antidepressant use and mortality in patients with cancer. To evaluate this, a large, nationwide, 4-year historical cohort study […]

Read More

Nivolumab Associated With Long-Term Survival in Multiple Tumors

Immunotherapy targeting the PD-1/PD-L1 axis has become a standard component of care across multiple tumor types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), and others. While these agents result in durable responses, there is limited data regarding long-term survival in these patients. In a secondary analysis of the phase I CA209-003 […]

Read More

Improving Treatment of Pancreatic Cysts

The majority of patients who develop pancreatic cysts require no treatment due to the benign nature of their cysts. However, a small percentage of cysts will develop into pancreatic cancer if left untreated, and early identification and treatment of pancreatic cancer is a major factor influencing patient outcomes. Current methods at identifying which patients require […]

Read More

New Model for Predicting Cancer Outcomes

Predicting the long-term outcomes and risk of progression in patients with cancer is an important component of care that can drive treatment strategies. Unfortunately, current risk prediction models are lacking and focus primarily on pretreatment factors such as tumor phenotype and patient characteristics, which are not always indicative of long-term outcome. The need for improved […]

Read More

Immune Checkpoint Inhibitors in Patients With NSCLC and Brain Metastases

Immune checkpoint inhibitors (ICI) targeting PD-1 and PD-L1 are a standard treatment for metastatic non-small cell lung cancer (NSCLC) across multiple lines of therapy for patients who do not possess targetable driver mutations. While as many as 40% of patients with advanced NSCLC will develop brain metastases during the course of their disease, patients with […]

Read More

No Value for Lymphadenectomy in Advanced Ovarian Cancer

Most patients with ovarian cancer are diagnosed in an advanced stage. The standard of care for these patients is maximal cytoreductive surgical debulking, followed by systemic treatment including platinum-based chemotherapy and targeted therapies (eg, bevacizumab, olaparib maintenance in patients harboring BRCA mutations). The goal of primary surgical cytoreduction is removal of as much of the […]

Read More